220 related articles for article (PubMed ID: 22323483)
1. A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide.
Dimopoulos MA; Richardson PG; Brandenburg N; Yu Z; Weber DM; Niesvizky R; Morgan GJ
Blood; 2012 Mar; 119(12):2764-7. PubMed ID: 22323483
[TBL] [Abstract][Full Text] [Related]
2. Secondary primary malignancies during the lenalidomide-dexamethasone regimen in relapsed/refractory multiple myeloma patients.
Kotchetkov R; Masih-Khan E; Chu CM; Atenafu EG; Chen C; Kukreti V; Trudel S; Tiedemann R; Reece DE
Cancer Med; 2017 Jan; 6(1):3-11. PubMed ID: 27860411
[TBL] [Abstract][Full Text] [Related]
3. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.
Stewart AK; Rajkumar SV; Dimopoulos MA; Masszi T; Špička I; Oriol A; Hájek R; Rosiñol L; Siegel DS; Mihaylov GG; Goranova-Marinova V; Rajnics P; Suvorov A; Niesvizky R; Jakubowiak AJ; San-Miguel JF; Ludwig H; Wang M; Maisnar V; Minarik J; Bensinger WI; Mateos MV; Ben-Yehuda D; Kukreti V; Zojwalla N; Tonda ME; Yang X; Xing B; Moreau P; Palumbo A;
N Engl J Med; 2015 Jan; 372(2):142-52. PubMed ID: 25482145
[TBL] [Abstract][Full Text] [Related]
4. Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma.
Dimopoulos MA; Chen C; Spencer A; Niesvizky R; Attal M; Stadtmauer EA; Petrucci MT; Yu Z; Olesnyckyj M; Zeldis JB; Knight RD; Weber DM
Leukemia; 2009 Nov; 23(11):2147-52. PubMed ID: 19626046
[TBL] [Abstract][Full Text] [Related]
5. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma.
Attal M; Lauwers-Cances V; Marit G; Caillot D; Moreau P; Facon T; Stoppa AM; Hulin C; Benboubker L; Garderet L; Decaux O; Leyvraz S; Vekemans MC; Voillat L; Michallet M; Pegourie B; Dumontet C; Roussel M; Leleu X; Mathiot C; Payen C; Avet-Loiseau H; Harousseau JL;
N Engl J Med; 2012 May; 366(19):1782-91. PubMed ID: 22571202
[TBL] [Abstract][Full Text] [Related]
6. Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial.
Jones JR; Cairns DA; Gregory WM; Collett C; Pawlyn C; Sigsworth R; Striha A; Henderson R; Kaiser MF; Jenner M; Cook G; Russell NH; Williams C; Pratt G; Kishore B; Lindsay J; Drayson MT; Davies FE; Boyd KD; Owen RG; Jackson GH; Morgan GJ
Blood Cancer J; 2016 Dec; 6(12):e506. PubMed ID: 27935580
[TBL] [Abstract][Full Text] [Related]
7. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.
Richardson PG; Oriol A; Beksac M; Liberati AM; Galli M; Schjesvold F; Lindsay J; Weisel K; White D; Facon T; San Miguel J; Sunami K; O'Gorman P; Sonneveld P; Robak P; Semochkin S; Schey S; Yu X; Doerr T; Bensmaine A; Biyukov T; Peluso T; Zaki M; Anderson K; Dimopoulos M;
Lancet Oncol; 2019 Jun; 20(6):781-794. PubMed ID: 31097405
[TBL] [Abstract][Full Text] [Related]
8. Review of therapy for relapsed/refractory multiple myeloma: focus on lenalidomide.
Mariz JM; Esteves GV
Curr Opin Oncol; 2012 Jan; 24 Suppl 2():S3-11. PubMed ID: 22245806
[TBL] [Abstract][Full Text] [Related]
9. Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial.
Yee AJ; Bensinger WI; Supko JG; Voorhees PM; Berdeja JG; Richardson PG; Libby EN; Wallace EE; Birrer NE; Burke JN; Tamang DL; Yang M; Jones SS; Wheeler CA; Markelewicz RJ; Raje NS
Lancet Oncol; 2016 Nov; 17(11):1569-1578. PubMed ID: 27646843
[TBL] [Abstract][Full Text] [Related]
10. Spotlight on lenalidomide in relapsed or refractory multiple myeloma.
Scott LJ; Lyseng-Williamson KA
BioDrugs; 2011 Oct; 25(5):333-7. PubMed ID: 21942918
[TBL] [Abstract][Full Text] [Related]
11. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Dimopoulos M; Spencer A; Attal M; Prince HM; Harousseau JL; Dmoszynska A; San Miguel J; Hellmann A; Facon T; Foà R; Corso A; Masliak Z; Olesnyckyj M; Yu Z; Patin J; Zeldis JB; Knight RD;
N Engl J Med; 2007 Nov; 357(21):2123-32. PubMed ID: 18032762
[TBL] [Abstract][Full Text] [Related]
12. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Weber DM; Chen C; Niesvizky R; Wang M; Belch A; Stadtmauer EA; Siegel D; Borrello I; Rajkumar SV; Chanan-Khan AA; Lonial S; Yu Z; Patin J; Olesnyckyj M; Zeldis JB; Knight RD;
N Engl J Med; 2007 Nov; 357(21):2133-42. PubMed ID: 18032763
[TBL] [Abstract][Full Text] [Related]
13. Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data.
Palumbo A; Bringhen S; Kumar SK; Lupparelli G; Usmani S; Waage A; Larocca A; van der Holt B; Musto P; Offidani M; Petrucci MT; Evangelista A; Zweegman S; Nooka AK; Spencer A; Dimopoulos MA; Hajek R; Cavo M; Richardson P; Lonial S; Ciccone G; Boccadoro M; Anderson K; Barlogie B; Sonneveld P; McCarthy PL
Lancet Oncol; 2014 Mar; 15(3):333-42. PubMed ID: 24525202
[TBL] [Abstract][Full Text] [Related]
14. [The use of lenalidomide in the treatment of multiple myeloma].
Holánek M; Hájek R
Klin Onkol; 2010; 23(2):67-72. PubMed ID: 20465083
[TBL] [Abstract][Full Text] [Related]
15. Subsequent primary malignancies among multiple myeloma patients treated with or without lenalidomide.
Rollison DE; Komrokji R; Lee JH; Hampras S; Fulp W; Fisher K; Baz R; Nishihori T; Xu Q; Olesnyckyj M; Kenvin L; Knight R; Sullivan D; Alsina M; Dalton W; Shain KH
Leuk Lymphoma; 2017 Mar; 58(3):560-568. PubMed ID: 27424609
[TBL] [Abstract][Full Text] [Related]
16. Intermittent granulocyte colony-stimulating factor for neutropenia management in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone.
Sun HL; Atenafu EG; Yeboah E; Reece DE; Trudel S; Kukreti V; Masih-Khan E; Winter A; Chen C
Leuk Lymphoma; 2015 Feb; 56(2):407-14. PubMed ID: 24738975
[TBL] [Abstract][Full Text] [Related]
17. Management of the relapsed/refractory myeloma patient: strategies incorporating lenalidomide.
Richardson P
Semin Hematol; 2005 Oct; 42(4 Suppl 4):S9-15. PubMed ID: 16344100
[TBL] [Abstract][Full Text] [Related]
18. Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium study.
Jakubowiak AJ; Richardson PG; Zimmerman T; Alsina M; Kaufman JL; Kandarpa M; Kraftson S; Ross CW; Harvey C; Hideshima T; Sportelli P; Poradosu E; Gardner L; Giusti K; Anderson KC
Br J Haematol; 2012 Aug; 158(4):472-80. PubMed ID: 22640031
[TBL] [Abstract][Full Text] [Related]
19. How lenalidomide is changing the treatment of patients with multiple myeloma.
Dimopoulos MA; Terpos E; Niesvizky R
Crit Rev Oncol Hematol; 2013 Oct; 88 Suppl 1():S23-35. PubMed ID: 23816163
[TBL] [Abstract][Full Text] [Related]
20. Is the risk of second primary malignancy increased in multiple myeloma in the novel therapy era? A population-based, retrospective cohort study in Taiwan.
Liu Y; Hou HA; Qiu H; Tang CH
Sci Rep; 2020 Sep; 10(1):14393. PubMed ID: 32873831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
